Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Blood (2024) 143 (3): 258–271.

https://doi.org/10.1182/blood.2022018905

Published: 2024

Includes: Supplemental data

Journal Articles

Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models

Blood (2023) 142 (Supplement 1): 6796.

https://doi.org/10.1182/blood-2023-179408

Published: 2023

Journal Articles

Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

Ismail Can, Reona Leo Sakemura, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, Kun Yun, Michelle J. Cox, Truc Huynh, James H. Girsch, Ekene J. Ogbodo, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Justin C. Boysen, Elizabeth L. Siegler, Atakan Ekiz, Saad S. Kenderian, Neil E. Kay

Blood (2022) 140 (Supplement 1): 8600–8601.

https://doi.org/10.1182/blood-2022-163446

Published: 2022

Journal Articles

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Kun Yun, Reona Leo Sakemura, Michelle J. Cox, Truc Huynh, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, James H. Girsch, Ekene J. Ogbodo, Ismail Can, Brooke Kimball, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Elizabeth L. Siegler, Mike Mattie, Sao-Mai Nguyen-Mau, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 10263–10264.

https://doi.org/10.1182/blood-2022-164706

Published: 2022

Journal Articles

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Carli M. Stewart, Michelle J. Cox, Reona Leo Sakemura, Ekene J. Ogbodo, Ismail Can, Claudia Manriquez-Roman, Kun Yun, Olivia Sirpilla, James H. Girsch, Truc Huynh, Elizabeth L. Siegler, Jenny J Kim, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 4536–4537.

https://doi.org/10.1182/blood-2022-160219

Published: 2022

Journal Articles

Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models

Olivia Sirpilla, Reona Leo Sakemura, Mehrdad Hefazi, James H. Girsch, Truc Huynh, Michelle J. Cox, Kendall J. Schick, Claudia Manriquez-Roman, Ismail Can, Kun Yun, Carli M. Stewart, Ekene J. Ogbodo, Elizabeth L. Siegler, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 1579–1580.

https://doi.org/10.1182/blood-2022-158872

Published: 2022

Journal Articles

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Blood (2022) 140 (Supplement 1): 2362–2364.

https://doi.org/10.1182/blood-2022-158273

Published: 2022

Journal Articles

Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions

Ismail Can, Sekar Natesampillai, Reona Leo Sakemura, Elizabeth L. Siegler, Claudia Manriquez-Roman, Shahrzad Jalali, Truc Huynh, Ashton Krogman, Mark Maynes, Andrew D. Badley, Saad S. Kenderian, Mehrdad Hefazi

Blood (2022) 140 (Supplement 1): 632–633.

https://doi.org/10.1182/blood-2022-163677

Published: 2022

Journal Articles

Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

Blood (2022) 139 (26): 3708–3721.

https://doi.org/10.1182/blood.2021012811

Published: 2022

Includes: Supplemental data

Journal Articles

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 901.

https://doi.org/10.1182/blood-2021-148591

Published: 2021

Journal Articles

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

Blood (2021) 138 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2021-145649

Published: 2021

Journal Articles

Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Blood (2021) 138 (Supplement 1): 2777.

https://doi.org/10.1182/blood-2021-149859

Published: 2021

Journal Articles

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142159

Published: 2020

Journal Articles

Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-139647

Published: 2020

Journal Articles

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy

Elizabeth L. Siegler, PhD, Brandon W Simone, Reona Sakemura, MDPhD, Erin E. Tapper, Paulina Horvei, MD, Michelle J. Cox, Mehrdad Hefazi, MD, Claudia Manriquez Roman, Ismail Can, Kendall J. Schick, Michael W. Ruff, MD, Stephen C Ekker, PhD, Saad S. Kenderian, MB, ChB

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141115

Published: 2020

Journal Articles

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Paulina Horvei, MD, Reona Sakemura, MD PhD, Michelle J. Cox, Michael W. Ruff, MD, Mehrdad Hefazi, MD, Erin E. Tapper, Kendall J. Schick, Claudia Manriquez Roman, Charles J. Kuhlmann, Juergen Schanzer, Jan Endell, Grzegorz Nowakowski, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 2859.

https://doi.org/10.1182/blood-2019-130506

Published: 2019

Journal Articles

Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)

Michelle J. Cox, Fabrice Lucien-Matteoni, PhD, Reona Sakemura, MD PhD, Justin C. Boysen, Yohan Kim, MS, Michael J. Hansen, Claudia Manriquez Roman, Erin E. Tapper, Sydney B. Crotts, Kendall J. Schick, Mehrdad Hefazi, MD, Paulina Roman Moreno, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 679.

https://doi.org/10.1182/blood-2019-125272

Published: 2019

Journal Articles

Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma

Reona Sakemura, MD PhD, Michelle J. Cox, Michael J. Hansen, Mehrdad Hefazi, MD, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Roman Moreno, MD, Michael W. Ruff, MD, Denise K Walters, PhD BSc, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 865.

https://doi.org/10.1182/blood-2019-123277

Published: 2019

Journal Articles

Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity

Reona Sakemura, MD PhD, Lukkana Suksanpaisan, PhD, Roman H Khadka, Alysha N Newsom, Michael J. Hansen, Michelle J. Cox, Mehrdad Hefazi, MD, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Roman Moreno, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Kah-Whye Peng, PhD, Stephen J Russell, MD PhD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 53.

https://doi.org/10.1182/blood-2019-123476

Published: 2019

Journal Articles

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, MD PhD, Sutapa Sinha, PhD, Raphael Mwangi, MS, Nancy Scott, MS, Mehrdad Hefazi, MD, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 3868.

https://doi.org/10.1182/blood-2019-129349

Published: 2019

NARROW

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models

Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions

Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy

Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro

Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)

Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma

Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only